Divi's Laboratories Ltd

Divis Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 6571, down 0.62% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.16% on the day, quoting at 24710.35. The Sensex is at 81322.01, down 0.16%.Divis Laboratories Ltd has added around 7.29% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 1.74% in last one month and is currently quoting at 21442.05, down 0.21% on the day. The volume in the stock stood at 1.4 lakh shares today, compared to the daily average of 6.21 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 6597.5, down 0.78% on the day. Divis Laboratories Ltd jumped 52.04% in last one year as compared to a 6.22% rally in NIFTY and a 13.43% spurt in the Nifty Pharma index.The PE of the stock is 79.46 based on TTM earnings ending March 25.Powered by Capital Market - Live

Divis Laboratories has entered into a long term manufacturing and supply agreement with a global pharma company. Under this agreement, the Company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. The Company expects meaningful revenue contribution from this long-term agreement. Cost of capacity addition for manufacturing under this agreement is estimated to be Rs.650-750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase wise under this Agreement. Powered by Capital Market - Live

As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term. To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer. Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space. The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024. Powered by Capital Market - Live

Divis Laboratories announced that the 35th Annual General Meeting(AGM) of the company will be held on 11 August 2025.Powered by Capital Market - Live

Revenue from operations grew by 12.24% year on year (YoY) to Rs 2,585 crore in the quarter ended 31 March 2025. Profit before tax for the quarter was at Rs 864 crore, up 21.17% from Rs 713 crore reported in the same period a year ago. Total expense stood at Rs 1,807 crore in Q4 FY25, up 8.26% on a YoY basis. The cost of material consumed was Rs 931 crore (up 3.67% YoY) and employee benefit expenses stood at Rs 350 crore (up 17.84% YoY) during the period under review. The company reported a forex gain of Rs 10 crore in Q4 FY25, compared to a loss of Rs 2 crore in Q4 FY24. On a standalone basis, the company's net profit surged 25.61% to Rs 667 crore on a 12.26% rise in revenue to Rs 2,536 crore in Q4 FY25 over Q4 FY24. For the financial year ended 31 March 2025, the company's consolidated net profit rose 36.93% YoY to Rs 2,191 crore. Revenue from operations grew 19.31% YoY to Rs 9,360 crore, compared to FY24. On the capex front, the company stated that the Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, commenced commercial operations during the current quarter. The company capitalised assets worth Rs 1,118 crore during the financial year, of which Rs 755 crore pertained to Unit III at Kakinada. Meanwhile, the company's board has recommended a dividend of Rs 30 per equity share for the financial year 2024'25, subject to approval by the members at the upcoming Annual General Meeting. Further, the company's board has approved the superannuation of L. Kishore Babu, Chief Financial Officer and Key Managerial Personnel, effective from 1 August 2025. The board placed on record its appreciation for Babu's contributions and leadership at Divi's Labs. Furthermore, the board has approved the appointment of Venkatesa Perumallu Pasumarthy as chief financial officer and key managerial personnel, also effective 1 August 2025. The appointment was recommended by the Nomination and Remuneration Committee and the Audit Committee of the company. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Powered by Capital Market - Live

Revenue from operations grew by 12.24% year on year (YoY) to Rs 2,585 crore in the quarter ended 31 March 2025. Profit before tax for the quarter was at Rs 864 crore, up 21.17% from Rs 713 crore reported in the same period a year ago. Total expense stood at Rs 1,807 crore in Q4 FY25, up 8.26% on a YoY basis. The cost of material consumed was Rs 931 crore (up 3.67% YoY) and employee benefit expenses stood at Rs 350 crore (up 17.84% YoY) during the period under review. The company reported a forex gain of Rs 10 crore in Q4 FY25, compared to a loss of Rs 2 crore in Q4 FY24. On a standalone basis, the company's net profit surged 25.61% to Rs 667 crore on a 12.26% rise in revenue to Rs 2,536 crore in Q4 FY25 over Q4 FY24. For the financial year ended 31 March 2025, the company's consolidated net profit rose 36.93% YoY to Rs 2,191 crore. Revenue from operations grew 19.31% YoY to Rs 9,360 crore, compared to FY24. On the capex front, the company stated that the Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, commenced commercial operations during the current quarter. The company capitalised assets worth Rs 1,118 crore during the financial year, of which Rs 755 crore pertained to Unit III at Kakinada. Meanwhile, the company's board has recommended a dividend of Rs 30 per equity share for the financial year 2024'25, subject to approval by the members at the upcoming Annual General Meeting. Further, the company's board has approved the superannuation of L. Kishore Babu, Chief Financial Officer and Key Managerial Personnel, effective from 1 August 2025. The board placed on record its appreciation for Babu's contributions and leadership at Divi's Labs. Furthermore, the board has approved the appointment of Venkatesa Perumallu Pasumarthy as chief financial officer and key managerial personnel, also effective 1 August 2025. The appointment was recommended by the Nomination and Remuneration Committee and the Audit Committee of the company. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Shares of Divis Laboratories gained 1.16% to end at Rs 6,281.35 on Friday, 16 May 2025. Powered by Capital Market - Live

Divis Laboratories announced that the Board of Directors of the Company at its meeting held on 17 May 2025, inter alia, have recommended the final dividend of Rs 30 per equity Share (i.e. 1500%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Divi's Laboratories rose 23.05% to Rs 662.00 crore in the quarter ended March 2025 as against Rs 538.00 crore during the previous quarter ended March 2024. Sales rose 12.24% to Rs 2585.00 crore in the quarter ended March 2025 as against Rs 2303.00 crore during the previous quarter ended March 2024. For the full year,net profit rose 36.94% to Rs 2191.00 crore in the year ended March 2025 as against Rs 1600.00 crore during the previous year ended March 2024. Sales rose 19.31% to Rs 9360.00 crore in the year ended March 2025 as against Rs 7845.00 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2585.002303.00 12 9360.007845.00 19 OPM %34.2431.74 -31.7128.11 - PBDT971.00808.00 20 3318.002541.00 31 PBT864.00713.00 21 2916.002163.00 35 NP662.00538.00 23 2191.001600.00 37 Powered by Capital Market - Live

Divis Laboratories will hold a meeting of the Board of Directors of the Company on 17 May 2025.Powered by Capital Market - Live

In its latest note, the broker highlighted Divi's strong potential to emerge as a primary supplier, backed by ongoing capacity expansion. It also noted the addition of Orforglipron'Eli Lilly's promising oral GLP-1 candidate'to Divi's development pipeline. The report further anticipates additional rounds of capital expenditure as product volumes scale up through 2030. Divi's is engaged in manufacturing of generic APIs, custom synthesis of active ingredients for innovator companies, other specialty chemicals and nutraceuticals. The company is focused on export markets within the domain of its capabilities. Divi's Laboratories' consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live